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Yoko Satoh1*, Atsushi Nambu2, Tomoaki Ichikawa3 and Hiroshi Onishi3Abstract
Background: In this retrospective study, the authors evaluated the prognostic value of whole-body total lesion
glycolysis (WTLG) on FDG/PET images in metastatic breast cancer (MBC) patients.
Methods: We retrospectively evaluated 54 MBC patients who were diagnosed as having one or more metastatic
lesions between June 2005 and March 2013. Twenty-four patients were diagnosed at the initial presentation (group
A) and 30 patients were diagnosed for the first time at some point after a surgery (group B). Patients were excluded
if they had received chemotherapy within 30 days before PET/CT. SUVmax and total TLG were calculated for all
lesions in each patient and the highest SUVmax and the whole-body TLG (WTLG) values were used as independent
variables for the analyses. Mean ages and the proportions of histopathological subtypes were compared between
two groups using Mann–Whitney U test and Fisher’s exact test, respectively. The prognostic significance of PET
parameters was assessed using Cox proportional hazards regression analysis.
Results: For groups A and B, the median follow-up period was 26 months (range, 3–58 months) and 40.5 months
(range, 3–69 months), and the median age was 61 years (range, 42–81 years) and 59 years (range, 24–74 years),
respectively. There were no significant differences between two groups in age (p = 0.294) or histopathological
subtype (p = 0.384). In the univariate analyses, WTLG was found to be significantly associated with overall survival (OS) for
patients of group A (p = 0.012). In the multivariate analysis, WTLG was also significantly associated with OS (p = 0.015).
Only hormonal receptor level was a significant indicator of longer OS in patients with recurrent MBC (group B).
Conclusions: This study demonstrated that WTLG on PET/CT is an independent prognostic factor for survival in breast
cancer patients with metastases at the initial presentation.Background
Breast cancer is now the most common cancer and is
one of the leading causes of cancer-related death among
women [1]. Breast cancer mortality has been declining
due to earlier detection of the disease and treatment that
is more effective than before [2]. However, despite im-
provements in the treatment of breast cancer over the
last decade, metastatic breast cancer (MBC) remains a
significant public health problem, since of the 1 million
women worldwide who are diagnosed annually with* Correspondence: pecampecam@yahoo.co.jp
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unless otherwise stated.early-stage breast cancer, approximately 33% will eventu-
ally experience relapse [3]. For these MBC patients,
prognostic information is crucial in order to facilitate
appropriate therapies for improving quality of life and
prolonging survival. Recently, not only hormone recep-
tors, such as estrogen receptor or progesterone receptor
(ER/PR), but also biomarkers that regulate tumor cell
proliferation, such as the Ki67 index or human epider-
mal growth factor receptor type 2 (HER2) status, have
been introduced as predictive indicators for prognosis
[4]. Since these indicators are derived from tissue speci-
mens from primary breast tumors at the time of first
diagnosis, they do not represent the whole extent of
disease. Therefore, more reliable prognostic indicatorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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malignancy of the disease in MBC patients are required.
Positron emission tomography (PET) has emerged
as an important molecular imaging technique in the
evaluation and clinical management of a number of neo-
plasms. Fluorine-18-fluorodeoxyglucose (FDG) PET has
already achieved wide acceptance for use in the initial
staging and restaging of cancers, the evaluation of re-
currence, and the monitoring of treatment effects in
patients with cancers, because its sensitivity and speci-
ficity for diagnosing malignancy are better than those
of other imaging methods. Furthermore, the standard-
ized uptake value (SUV) of primary tumors has already
been shown to be of value as a prognostic indicator of
survival in patients with operable breast cancer [5].
FDG PET may also allow measurement of the tumor
burden in relation to the degree of malignancy. The
high tumor-to-background intensity ratios in FDG PET
enable computer-assisted measurement of total body
metabolic tumor volume or total lesion glycolysis (TLG).
As a prognostic factor in MBC patients, FDG PET eval-
uations may be more advantageous over assessments
involving hormone receptors or biomarkers that regu-
late tumor cell proliferation, which require tissue sam-
pling. This is because FDG PET can directly evaluate
the extent of metastatic disease as well as total tumor
burden without biopsy. In addition, as volume is not
one of the constituents of SUV, TLG may be a better
prognostic factor than SUV. Thus, the PET parameters
of metastatic sites in MBC patients at the initial presen-
tation, or at the time of recurrence, may provide im-
portant information about the aggressiveness of whole
tumors that could be of prognostic significance. Therefore,
the objective of this study was to evaluate the predictive
performance of TLG-based FDG PET/CT assessments in
MBC patients.Methods
This study was approved by the Ethics Committee of the
Kofu Neurosurgical Hospital. All patients gave written
informed consent for future anonymous use of clinical
data in clinical study.Patients
We conducted this retrospective study of patients with
breast cancer who underwent FDG PET/CT between
June 2005 and December 2012 at a single institution. A
total of 148 breast cancer patients were suspected of
having metastatic disease on the basis of FDG PET/CT
assessments. Medical records were reviewed to gather
clinical data, including information on age, histology,
tumor phenotype (ER, PR, and HER2 expression), and
final outcome.PET/CT images were obtained within 60 days of MBC
diagnosis in all patients. The date of MBC diagnosis was
defined as the date when the patient underwent biopsy
of a metastatic site or the date of radiological examina-
tions at the first confirmed metastasis. Patients who
already had shown MBC, a history of other malignan-
cies, or had received chemotherapy within 30 days be-
fore PET/CT imaging were excluded. However, receiving
endocrine therapies during this period was not consid-
ered a criterion of exclusion. The reasons for exclusion
of patients are summarized in Figure 1. A total of 54
MBC patients were eventually eligible for this study.
Twenty-four patients were at the initial presentation
stage (group A) and the remaining 30 patients were at
the first recurrence stage (i.e., newly diagnosed as having
MBC after a surgery; group B). Table 1 summarizes pa-
tient characteristics, tumor phenotypes, and initial clin-
ical stages.
The diagnosis of MBC was based on histopathological
diagnosis of a metastatic site or the findings of conven-
tional imaging examinations, such as ultrasound, bone
scan, CT, or magnetic resonance imaging. As for the im-
aging diagnoses of MBC, the diagnostic criteria were
based on the presence of the following lesions: newly
appearing lesions on a follow-up examination; lesions
increasing in size; or lesions that had decreased in size
on the follow-up examinations after additional treat-
ments, such as chemotherapy, radiation therapy, or mo-
lecular targeted drug therapy. The median follow-up
periods were 26 months (range, 3–58 months) and
40.5 months (range, 9–69 months), and the median ages
were 61 years (range, 42–81 years) and 59 years (range,
24–74 years), for group A and B after the diagnoses of
MBC, respectively.
PET/CT
All patients fasted for at least 6 hours before the FDG-
PET examination, although oral hydration with glucose-
free water was allowed. After peripheral blood glucose
level was confirmed to be <150 mg/dL, patients received
an intravenous injection of 3 MBq/kg of FDG. The FDG
used for the PET scans was produced at the biochemical
cyclotron facility in the PET center at Kofu Neurosurgical
Hospital. All whole-body PET/CT images were obtained
using a PET/CT scanner (Biograph Duo LSO; Siemens
Medical Solutions; Erlangen, Germany) consisting of a
PET scanner and a 2-detector row CT scanner. The axes
of both systems were mechanically aligned so that the
patient could be moved from the CT scanner to the
PET scanner gantry. Thus, the resulting PET and CT
scans co-registered on the same hardware. PET/CT
scanning was performed from the center of the skull to
the upper thigh 60 min after the injection. CT was per-
formed using the following settings: 110 kVp; 30 mA;
Patients who were suspected of having metastatic breast cancer and underwent FDG PET/CT from June  
2005 to December 2012 (n = 148)
Excluded patients (n = 94)
False positive on PET/CT (i.e. finally not MBC, n = 5)
Receiving chemotherapy within 30 days before FDG PET/CT (n = 3)
History of previous MBC* (n = 65)
Bone metastasis (n = 37)
Lung metastasis (n = 36)
Lymph node metastasis (n = 30)
Liver metastasis (n = 15)
Pleural dissemination (n = 1)
Peritoneal dissemination  (n = 1)
Fibrosarcoma (in irradiated fields) (n = 2)
*33/65 patients of had two or more metastatic sites
History of previous other malignancy (n = 2 , Rectum 1, Lung 1)
Fatal coexistent disease (n = 1)
Lost to follow-up (n = 18)
Eligible patients (n = 54)
at the first presentation of breast cancer; Group A (n = 24)
at the first recurrence of breast cancer; Group B (n = 30)
Figure 1 Reasons for exclusion of patients and the number of eligible patients. The reasons for exclusion and the number of eligible
patients are shown in the figure. Abbreviations: FDG, [18 F]-2-fluoro-2-deoxy-D-glucose; PET/CT, positron emission tomography/computed
tomography; MBC, metastatic breast cancer.
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verse field of view, 50 cm; and section thickness, 2.5 mm.
The patients maintained normal shallow respirations
during the CT scans. No iodinated contrast material was
administered. The PET scans were performed immediately
after the CT scans, with an identical transverse field of
view. The PET scans were acquired in a 3-dimensional
mode with a matrix size of 128 × 128. After the transmis-
sion scan, the PET acquisition time was 2 min for each
table position. The CT data was resized, from a 512 × 512matrix to a 128 × 128 matrix, to match the PET data,
so that the scans could be fused and CT-based trans-
mission maps could be generated. PET data sets were
iteratively reconstructed using an ordered subset expect-
ation maximization algorithm and segmented attenuation
correction (2 iterations, 8 subsets). Integrated, co-registered
PET/CT images on three orthogonal (transaxial, coronal
and sagittal) planes were reviewed on a workstation (e-soft-
PET; Siemens Medical Solutions), which enabled image
fusion and analysis.
Table 2 Numbers of patients showing metastasis at
various sites
Site of metastasis Group A* (n = 24) Group B** (n = 30)
Axillary lymph node 22 (91.7%) 7 (23.3%)
Extra-axillary lymph node 7 (29.2%) 13 (43.3%)
Bone 4 (16.7%) 9 (30%)
Liver 1 (4.2%) 2 (6.7%)
Lung 3 (12.5%) 4 (13.3%)
Pleural dissemination 0 (0%) 1 (3.3%)
*Group A: Cases found to have metastases at the initial presentation.
**Group B: Cases found to have newly diagnosed metastases at some point
after a surgery.











HER2 positive 5 5 0.695
Triple negative 2 6 0.277














Median (range) 26 (3–58) 40.5 (9–69)
*Group A: Cases found to have metastases at the initial presentation.
**Group B: Cases found to have newly diagnosed metastases at some point
after a surgery.
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER human
epidermal growth factor 2.
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Experienced nuclear medicine physicians prospectively
interpreted PET/CT images with other available imaging
examinations (e.g., previous CT). FDG uptake was evalu-
ated on the basis of a region-of-interest analysis.
A nuclear medicine physician (Y.S.) with 10 years’
experience in PET/CT interpretation analyzed all FDG
PET/CT images semi-quantitatively by using dedicated
software (e-soft-PET; Siemens Medical Solutions).
All lesions were evaluated separately. The SUVs were
acquired using attenuation-corrected images. From PET/
CT scans, the maximum SUV (SUVmax) and metabolic
tumor volume (MTV) were calculated. The software cre-
ated a 3D contour around voxels that were equal to or
greater than 50% of the maximum voxel value inside the
spherical region. This volume was defined as the MTV.
The threshold of 50% was used in accordance with the
findings of a prior publication [6]. Among the SUVmax
values of all the lesions in each patient, the highest SUV-
max (HSUVmax) value was used for the analysis. Total
lesion glycolysis (TLG) was calculated as MTV multiplied
by the mean SUV (TLG = MTV × mean SUV). Whole-body TLG (WTLG) was calculated as the sum of the TLG
values of all lesions in each patient.
Statistical analysis
Statistical analysis was performed using the PASW
Statistics 18 (SPSS; Chicago, USA).
Mean ages and the proportions of histopathological
subtypes and phenotypes were compared between the
two groups using Mann–Whitney U test and Fisher’s
exact test, respectively. No correction for multiple com-
parisons was made. Univariate and multivariate analyses
were performed to evaluate the effects of the highest
SUVmax, WTLG, and other clinical variables on overall
survival (OS), using Cox proportional hazards regression
analysis. Overall survival was defined as the period of time
from the day of diagnosis of MBC to the day of death or
final clinical follow-up. In group A, where the primary
breast cancers of these patients had not been resected,
additional analyses were performed including SUVmax of
the primary breast cancers as an independent variable.
Since independent variables with a high correlation
coefficient may lead to multicollinearity, correlations be-
tween the independent variables in the multivariate ana-
lyses had been calculated in advance, using the Pearson’s
correlation coefficient or Spearman’s rank correlation
coefficient. Survival rates were calculated using the
Kaplan–Meier method. All tests were 2-sided, and p values
less than 0.05 were considered statistically significant.
Results
There were no significant intergroup differences in age
(p = 0.393), histopathological subtype (p = 0.384), and phe-
notypes: ER/PR-positive and HER2-negative (p = 0.783),
HER2-positive (p = 0.695), and triple-negative (p = 0.277).
Median HSUVmax and WTLG were 6.32 (range, 1.72-
15.21) and 59.92 (range, 3.62-1904.3) for group A, and
4.48 (range, 1.28-12.06) and 12.38 (range, 0.7-243.64) for
group B, respectively. The numbers of patients with
metastases in anatomic sites are shown in Table 2. The
mean number (range) of metastases was 2.3 (1–10) and
2.2 (1–7) in groups A and B, respectively. In group A,
Satoh et al. BMC Cancer 2014, 14:525 Page 5 of 7
http://www.biomedcentral.com/1471-2407/14/525no metastatic lesion was diagnosed histopathologically
prior to treatment. Although all patients treated with
surgery (16/24) in group A underwent histopathological
assessments to confirm if they had axillary lymph node
metastasis, pretreatment imaging findings were used for
the analyses in patients who received neoadjuvant chemo-
therapy (9/16). In group B, 6 metastatic lesions (axillary
lymph node: 4, subclaviclar lymph node: 1, supraclaviclar
lymph node: 1) were histopathologically diagnosed.
In the univariate and multivariate analyses for group
A, WTLG was a significant predictor of OS, while
HSUVmax and tumor phenotype (ER/PR-positive and
HER2-negative, and triple negative) were not statisti-
cally significant predictors of OS (Table 3). On the
other hand, in the univariate and multivariate analyses
for group B, the ER/PR-positive and HER2-negative
phenotype were significant predictors while HSUVmax
and WTLG were not significant predictors (Table 3).
SUVmax of primary breast cancer was not a significant
predictor for OS in the univariate and multivariate ana-
lyses for group A (p = 0.136, 0.429, Additional file 1:
Table S4). Tumor staging was not a significant predictor
for OS in both univariate and multivariate analyses (data
not shown). Correlation coefficients between age, tumor
phenotype (ER/PR-positive and HER2-negative), HSUV-
max, and WTLG are shown in Additional file 2: Table
S5. At 3 years, OS of group A and group B was 77.4%
and 86.4%, respectively.
Discussion
Prognostic factors used in breast cancer can broadly be
divided into those that determine the extent of disease
(i.e., tumor staging) and those that determine biological
tumor characteristics. The latter are now crucial not
only in predicting prognosis but also in selecting an
appropriate treatment regimen [7-9]. In addition, the
usefulness of PET parameters in breast cancer has alsoTable 3 Univariate and multivariate analyses for overall
survival in group A* using Cox model
HR 95% CI p
Univariate analysis
Age 0.989 0.927-1.054 0.727
ER/PR(+) 0.203 0.033-1.248 0.085
highest SUVmax 1.145 0.895-1.466 0.282
WTLG 1.004 1.001-1.006 0.012*
Multivariate analysis
ER/PR(+) 0.273 0.017-4.329 0.357
highest SUVmax 0.792 0.503-1.245 0.312
WTLG 1.004 1.0011.007 0.015*
*Group A: Cases found to have metastases at the initial presentation.
Abbreviations: ER estrogen receptor, PR progesterone receptor, SUV standardized
uptake value, WTLG whole-body total lesion glycolysis.been reported currently [5,10,11]. However, although
many authors have advocated that the SUVmax of
FDG PET is an important predictor of progression
after treatment, the clinical importance of SUVmax as
a prognostic factor for malignancy is still controversial
[12,13]. Because SUVmax is a single-voxel-based value,
it may not be an adequate surrogate marker for the
true biology of the whole tumor. In addition, SUVmax
is susceptible to statistical noise and thus may be an
unstable parameter. On the other hand, it has been
reported that volume-based parameters (e.g., metabolic
tumor volume, MTV, TLG, etc.) were significantly
associated with an increased risk of recurrence and
death in patients with surgically resected non-small
cell lung cancer [14].
Volume-based parameters of FDG PET represent the
metabolic tumor burden of disease, reflecting both
tumor volume and glucose utilization rate. These indi-
ces have been considered to be potentially reliable pa-
rameters for providing more details about the status of
diseases in various types of cancers, especially lung
tumors, oro/nasopharyngeal, and rectal cancers [15-18].
Most recently, some authors have reported that TLG was
superior to SUVmax as a predictor of prognosis in malig-
nancies [19,20]. Our results showed that the WTLG of
MBC in the initial presentation (group A) was correlated
with OS not only in the univariate analysis but also in the
multivariate analysis after adjustments for tumor pheno-
type and HSUVmax. Since ER/PR status was not a signifi-
cant prognostic factor in our analyses, it could be said that
WTLG is a better predictor of prognosis than ER/PR
status in MBC patients at the initial presentation. Fur-
thermore, SUVmax of primary breast cancers was not a
significant predictor of OS in the multiple variable ana-
lysis as well as in the univariate analysis. Thus, WTLG
may be considered a better prognostic factor than SUV-
max in primary breast cancer patients who show meta-
static disease at the initial presentation.
Conversely, the univariate and multivariate analyses
for group B identified only ER/PR status as an independ-
ent prognostic factor. This result might suggest that
WTLG does not accurately represent the extent of
disease in recurrent breast cancers. This result may be
explained by considering the finding that a similar num-
ber of patients in group B whose tumors were ER/PR
positive had received endocrine therapy (14/20 [70%],
aromatase inhibitor or antiestrogen). At the time of FDG
PET/CT, FDG accumulation in MBC may have been
diminished by the effects of these hormonal drugs, when
compared with FDG accumulation in MBC at the first
presentation. FDG PET/CT may be inappropriate for
estimating the inherent malignancy or the extent of
MBC when patients are receiving chemotherapy, includ-
ing endocrine therapy. Morris et al. [21] reported that
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significantly correlated with OS, and with the same
group of patients, Ulaner GA et al. [22] also have re-
cently reported that the TLG tertile in the multivariate
analysis was significantly associated with OS in patients
with bone metastasis. We did not perform individual
analyses for each metastatic site because of the insuffi-
cient sample size in our study. While their observations
were inconsistent with our results that TLG was not a
significant prognostic factor in patients with recurrence
after a surgery (group B), this difference might be caused
by the smaller sample size.
There were a few limitations to our study. First, be-
cause of the retrospective nature of this study, the
patient population in our study was heterogeneous in
terms of follow-up strategy (e.g., follow-up period and
choice of imaging modality) and treatment regimens.
Second, the number of the study subjects was relatively
small, as we mentioned before.
Conclusions
In summary, the present study suggested that a higher
WTLG, as a volumetric parameter of FDG PET, predicts
worse OS in MBC patients at their initial presentation.
A further prospective study to validate our results would
be warranted.
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